Anthropic’s $1.5T IPO: Four ways it aims to disrupt science
Anthropic completed the largest initial public offering on record on 19 November, reaching a valuation of about $1.5 trillion, and has announced major ambitions to disrupt science, including curing diseases and accelerating discovery. The San Francisco-based maker of the AI model Claude was founded in 2021 by former OpenAI employees and has launched directed science efforts in quantum mechanics, protein design, and mathematics, opening its first life sciences laboratory this year. All seven founders have pledged to donate 80% of their equity to charity, and the company established the Anthropic Public Benefit Fund with an initial 5% share commitment. Researchers have criticized Anthropic’s timelines for curing complex diseases as unrealistic and raised concerns about risks from developing superintelligent AI, including existential threats to humanity. The company’s early biological results, such as finding a CRISPR-like system and designing protein binders, received mixed receptions, though some experts praised its transparency in protein design work.